How to buy PTC Therapeutics stock (PTCT)

PTC Therapeutics is a biotechnology business based in the US. PTC Therapeutics shares (PTCT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $46.24 – a decrease of 0.28% over the previous week. PTC Therapeutics employs 988 staff and has a trailing 12-month revenue of around $900.7 million.

Our top picks for where to buy PTC Therapeutics stock

Buy PTC Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

PTC Therapeutics stock price (NASDAQ: PTCT)

Use our graph to track the performance of PTCT stocks over time.

PTC Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$46.24
52-week range	$23.58 - $54.16
50-day moving average more info button	$43.03
200-day moving average more info button	$35.26
Wall St. target price	$58.71
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.94

Is it a good time to buy PTC Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PTC Therapeutics price performance over time

Historical closes compared with the close of $46.24 from 2024-12-20

1 week (2024-12-13)	-0.28%
1 month (2024-11-22)	6.96%
3 months (2024-09-20)	26.20%
6 months (2024-06-21)	26.62%

1 year (2023-12-21)	62.70%
2 years (2022-12-21)	22.13%
3 years (2021-12-21)	15.34%
5 years (2019-12-20)	48.57

Is PTC Therapeutics stock undervalued or overvalued?

Valuing PTC Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PTC Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

PTC Therapeutics's PEG ratio

PTC Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.81. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PTC Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

PTC Therapeutics's EBITDA

PTC Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.8 million.

The EBITDA is a measure of a PTC Therapeutics's overall financial performance and is widely used to measure a its profitability.

PTC Therapeutics financials

Revenue TTM	$900.7 million
Gross profit TTM	$2.6 million
Return on assets TTM	-5.15%
Return on equity TTM	-7740.12%
Profit margin	-50.32%
Book value	$-13.70
Market Capitalization more info button	$3.5 billion

TTM: trailing 12 months

PTC Therapeutics share dividends

We're not expecting PTC Therapeutics to pay a dividend over the next 12 months.

PTC Therapeutics share price volatility

Over the last 12 months, PTC Therapeutics's shares have ranged in value from as little as $23.58 up to $54.16. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PTC Therapeutics's is 0.628. This would suggest that PTC Therapeutics's shares are less volatile than average (for this exchange).

PTC Therapeutics overview

PTC Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc.

Frequently asked questions

What percentage of PTC Therapeutics is owned by insiders or institutions?
Currently 2.342% of PTC Therapeutics shares are held by insiders and 104.125% by institutions. How many people work for PTC Therapeutics?
Latest data suggests 988 work at PTC Therapeutics. When does the fiscal year end for PTC Therapeutics?
PTC Therapeutics's fiscal year ends in December. Where is PTC Therapeutics based?
PTC Therapeutics's address is: 100 Corporate Court, South Plainfield, NJ, United States, 07080 What is PTC Therapeutics's ISIN number?
PTC Therapeutics's international securities identification number is: US69366J2006 What is PTC Therapeutics's CUSIP number?
PTC Therapeutics's Committee on Uniform Securities Identification Procedures number is: 69366J200